Image credit: Freepik
Bio-healthcare company Dx&Vx (DXVX) has accelerated the development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide.
The vaccine under development uses a virus-like particle (VLP) platform, which offers greater stability and ease of storage compared to mRNA vaccines. Theoretically, it has the potential to prevent infections caused by all known and future COVID-19 variants.
Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.
DXVX also acquired a universal COVID-19 treatment technology last year from LUCA AI Cell. DXVX stated, "Luca's treatment technology has efficacy test data for dozens of lethal viruses, including COVID-19," and added, "It is expected to enable the development of a new-concept COVID-19 treatment.".
In addition to its universal COVID-19 vaccine and treatment, Dx&Vx (DXVX) is actively targeting the global pharmaceutical and biotech market through a diverse pipeline, including:
The mRNA vaccine platform enables the production of vaccines designed for long-term storage at room temperature, enabling vaccine production even in areas with limited cold-chain infrastructure, thereby reducing geographical barriers.
